available evidence favours resumption of anticoagulation therapy for gastrointestinal tract bleeding and intracranial hemorrhage survivors, and it is reasonable to begin postbleeding decision making with resuming anticoagulation therapy as the default plan
advice in the context of restarting anticoagulation - either warfarin or DOAC anticoagulation - because "it seems reasonable to assume that the risks and benefits of resuming DOAC anticoagulation therapy will be largely similar to those associated with resuming warfarin therapy because these agents have shown similar if not superior efficacy and safety to warfarin in clinical trials" (1)
after considering factors related to the index bleeding event, the underlying thromboembolic risk, and comorbid conditions, a decision to accept or modify the default plan can be made in collaboration with other care team members, the patient, and their caregivers
restarting oral anticoagulation after gastrointestinal bleeding
although additional information is needed regarding the optimal timing of anticoagulation resumption, available evidence indicates that waiting approximately 14 days may best balance the risk of recurrent bleeding, thromboembolism, and mortality after gastrointestinal tract bleeding (1)
when to resume anticoagulation after intracranial hemorrhage (ICH) is less clear, but most studies indicate that resumption within the first month of discharge is associated with better outcomes (1)
a review states (2):
anticoagulation resumption does not increase the risk of recurrent ICH and can also reduce the risk of all-cause mortality
anticoagulation cessation exposes patients to a significantly higher risk of thromboembolism, which could be reduced by resumption
optimal timing of anticoagulation resumption after ICH is still unknown
both early (< 2 weeks) and late (> 4 weeks) resumption should be reached only after very careful assessment of risks for ICH recurrence and thromboembolism
it has been suggested that “early resumption” (within 2 weeks) of oral anticoagulation (OAC) therapy in patients with a high risk of thromboembolism, and “late resumption” (after 4 weeks) in patients with a high risk of ICH
introduction of new oral anticoagulants and other interventions, such as left atrial appendage closure, has provided some patients with more alternatives
the European Heart Rhythm Association guidelines recommend that OAC may be restarted after 4–8 weeks after ICH, if the risk of thromboembolism is high and the risk of recurrent ICH is low (3)
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.